These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29794145)

  • 1. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of
    Eskelund CW; Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Pedersen LB; Geisler CH; Jerkeman M; Grønbæk K
    Haematologica; 2018 Nov; 103(11):e541-e543. PubMed ID: 29794145
    [No Abstract]   [Full Text] [Related]  

  • 2. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
    Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
    Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
    [No Abstract]   [Full Text] [Related]  

  • 3. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
    Gressin R; Daguindau N; Tempescul A; Moreau A; Carras S; Tchernonog E; Schmitt A; Houot R; Dartigeas C; Pignon JM; Corm S; Banos A; Mounier C; Dupuis J; Macro M; Fleury J; Jardin F; Sarkozy C; Damaj G; Feugier P; Fornecker LM; Chabrot C; Dorvaux V; Bouadallah K; Amorin S; Garidi R; Voillat L; Joly B; Celigny PS; Morineau N; Moles MP; Zerazhi H; Fontan J; Arkam Y; Alexis M; Delwail V; Vilque JP; Ysebaert L; Le Gouill S; Callanan MB;
    Haematologica; 2019 Jan; 104(1):138-146. PubMed ID: 30171024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of
    Carras S; Torroja A; Emadali A; Montaut E; Daguindau N; Tempescul A; Moreau A; Tchernonog E; Schmitt A; Houot R; Dartigeas C; Barbieux S; Corm S; Banos A; Fouillet L; Dupuis J; Macro M; Fleury J; Jardin F; Sarkozy C; Damaj G; Feugier P; Fornecker LM; Chabrot C; Dorvaux V; Bouabdallah K; Amorim S; Garidi R; Voillat L; Joly B; Morineau N; Moles MP; Zerazhi H; Fontan J; Arkam Y; Alexis M; Delwail V; Vilque JP; Ysebaert L; Burroni B; Callanan M; Le Gouill S; Gressin R
    Haematologica; 2024 Jun; 109(6):1857-1865. PubMed ID: 38031755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.
    Obr A; Klener P; Furst T; Kriegova E; Zemanova Z; Urbankova H; Jirkuvova A; Petrackova A; Malarikova D; Forsterova K; Cudova B; Sedlarikova L; Berkova A; Kasalova N; Papajik T; Trneny M
    Br J Haematol; 2020 Dec; 191(5):e103-e106. PubMed ID: 32862455
    [No Abstract]   [Full Text] [Related]  

  • 8. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
    Smith MR; Jegede OA; Martin P; Till BG; Parekh SS; Yang DT; Hsi ED; Witzig T; Dave S; Scott D; Hanson C; Kostakoglu Shields L; Abdel-Samad N; Casulo C; Bartlett NL; Caimi PF; Al Baghdadi T; Blum KA; Romer MD; Inwards DJ; Lerner RE; Wagner LI; Little RF; Friedberg JW; Leonard JP; Kahl BS
    Blood; 2024 Sep; 144(10):1083-1092. PubMed ID: 38820500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
    Armand P; Redd R; Bsat J; Mayuram S; Giardino A; Fisher DC; LaCasce AS; Jacobson C; Davids MS; Brown JR; Weng L; Wilkins J; Faham M; Freedman AS; Joyce R; Jacobsen ED
    Br J Haematol; 2016 Apr; 173(1):89-95. PubMed ID: 26729345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
    Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
    Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
    [No Abstract]   [Full Text] [Related]  

  • 11. Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
    Lindberg Å; Eskelund CW; Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Grønbaek K; Geisler CH; Jerkeman M
    Hematol Oncol; 2022 Feb; 40(1):22-30. PubMed ID: 34713465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma.
    Lamm W; Kiesewetter B; Puhr H; Dolak W; Mayerhöfer ME; Raderer M
    Ann Hematol; 2019 Jun; 98(6):1519-1520. PubMed ID: 30547188
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
    Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
    Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temsirolimus acts as additive with bendamustine in aggressive lymphoma.
    Zoellner AK; Weiglein T; Hutter G; Zimmermann Y; Cieplik HC; Hess G; Dreyling M
    Ann Hematol; 2016 Feb; 95(3):403-7. PubMed ID: 26658770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
    Cencini E; Sicuranza A; Fabbri A; Ferrigno I; Rigacci L; Cox MC; Raspadori D; Bocchia M
    Br J Haematol; 2019 Jan; 184(2):223-231. PubMed ID: 30203425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.
    Bond DA; Huang Y; Ruppert AS; Walker AR; Dotson EK; Roddy J; Blum KA; Christian BA
    Leuk Lymphoma; 2017 Jul; 58(7):1589-1597. PubMed ID: 27838951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.
    Fu S; Wang M; Zhao H; Li R; Lairson DR; Giordano SH; Zhao B; Du XL
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e616-e623. PubMed ID: 31563564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
    Hitz F; Zucca E; Pabst T; Fischer N; Cairoli A; Samaras P; Caspar CB; Mach N; Krasniqi F; Schmidt A; Rothermundt C; Enoiu M; Eckhardt K; Berardi Vilei S; Rondeau S; Mey U
    Br J Haematol; 2016 Jul; 174(2):255-63. PubMed ID: 27018242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
    Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
    N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.